TITLE

Pfizer reviews agencies for major drug launches

AUTHOR(S)
Goetzl, David; Snyder, Beth; Petrecca, Laura
PUB. DATE
December 1999
SOURCE
Advertising Age;12/6/1999, Vol. 70 Issue 50, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
This article reports that Pfizer is in the final stages of selecting advertising agencies for two new drugs yet to receive approval from the U.S. Food and Drug Administration as of December 6, 1999. A decision is expected for the estimated $40 million account for Relpax, an anti-migraine drug expected to come to market in 2000 since it received clearance from the U.S. government. Soon after, a decision is expected on a new arthritis treatment, a second-generation drug to Pfizer's wildly successful Celebrex.
ACCESSION #
2558266

 

Related Articles

  • Painkiller a jackpot for NU, chemist. Merrion, Paul // Crain's Chicago Business;3/22/2004, Vol. 27 Issue 12, p1 

    Around Northwestern University, all they can talk about is the "drug money." That's the expected windfall of well over $100 million a year in royalties the school will split with an unassuming 57-year-old professor who came up with a powerful and versatile painkiller that New York-base Pfizer...

  • Pipeline.  // Medical Marketing & Media;Jan2009, Vol. 44 Issue 1, p10 

    The article offers news briefs related to medicine in the U.S. The Food and Drug Administration (FDA) approved Pfizer Inc.'s Selzentry tablets. FDA approved Schering-Plough to market its hepatitis C combination therapy consisting Pegintron and Rebetol. The Boostrix vaccine of GlaxoSmithKline was...

  • Pfizer Reports Results From 3 Phase 4 Studies Demonstrating EMBEDA(r) (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII Impact On Drug Liking And Withdrawal Symptoms.  // Biomedical Market Newsletter;12/28/2011, Vol. 21, p1 

    The article provides information related to a study conducted by Pfizer Inc. for the development of EMBEDA (morphine sulfate and naltrexone hydrochloride) drug. It is mentioned that the drug has been approved by the U.S. Food & Drug Administration to be used as an analgesic to relief the...

  • Remoxy: more work needed for FDA approval.  // Reactions Weekly;7/9/2011, Issue 1359, p3 

    The article reports on the rejection received by Pfizer from the U.S. Food and Drug Administration (FDA) for its extended-release formulation Remoxy.

  • Celebrex Loses FAP Indication.  // BioWorld Today;6/11/2012, Vol. 23 Issue 112, p6 

    The article reports on the decision of the U.S. Food and Drug Administration to pull out its 12-year-old accelerated approval for Celebrex, the drug for familial adenomatous polyposis (FAP) from Pfizer Inc. because the postmarketing study required to verify the clinical benefit was not completed.

  • Pharma: Other News To Note.  // BioWorld Today;11/6/2013, Vol. 24 Issue 214, p13 

    The article informs that Pfizer Inc. has announced that the U.S. Food and Drug Administration (FDA) approved a prior approval supplement for Embeda extended-release capsule Schedule II Controlled Substance (CII).

  • FDA approves new treatment for menopause.  // Hill;10/7/2013, Vol. 20 Issue 113, p15 

    The article reports that U.S. Feederal Drug Administration (FDA) has approved the utilization of Duavee, a drug that prevents menopausal osteoporosis and other symptoms, developed by Pfizer Inc.

  • Pfizer, Inc.; Withdrawal of Approval of Familial Adenomatous Polyposis Indication for CELEBREX. Woodcock, Janet // Federal Register (National Archives & Records Service, Office of;6/8/2012, Vol. 77 Issue 111, p34052 

    The article presents information on a notice issued by the U.S. Food and Drug Administration regarding the withdrawal of approval for the familial adenomatous polyposis for celecoxib capsules which is offered by Pfizer Inc.

  • The Class of 2012 for New Molecular Entities and Biologies. Van Arnum, Patricia // Pharmaceutical Technology;Dec2012, Vol. 36 Issue 12, p46 

    The article offers information on the new molecular entities (NMEs) and biologics license applications (BLAs) or active pharmaceutical ingredients (APIs) and excipients approved by the U.S. Food and Drug Administration (FDA) in 2012. It states that the Center for Drug Evaluation and Research...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics